Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients

Table 2 Study design, patient flow and samples taken during the study

Week 1 n = 54^a	Week 2 n = 50^b	Week 3 n = 49^c	Week 4 n = 47^d	Week 5 (n:44)^e
Week 1 n = 54^a	Week 2 n = 50^b	Week 3 n = 49^c	Week 4 n = 47^d	Day 1	Day 2
Inclusion hsCRP, PTX3, orosumucoid	hsCRP, PTX3, orosomucoid	hsCRP, PTX3, orosomucoid	hdCRP, PTX3, orosomucoid	Administration of 100 mg quinine	hdCRP, PTX3, IL-6 and orosomucoid Hb, P-Iron, P-albumin, NT-pro-BNB and PTH 4β-OH-Cholesterol and P-Cholesterol Concentrarion of quinine and 3-OH-quinine

^aAt screening, ^bFour patients decided to withdraw their consent and did not continue with the study, ^cOne patient underwent kidney transplantation, ^dTwo patients died before completing the study, ^eThree patients were excluded; one due to an infectious episode and two because of undetectable levels of quinine and 3-OH-quinine in plasma

ISSN: 2050-6511